TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

94 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

83 studies on the map

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma — Allervie Clinical Research, BirminghamA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA) — Research Site, MobileA Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma — AMR Clinical, TempeA Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma — Research Site, MontgomeryA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. — Research Site, SurpriseVENTURI (VENTilation Using Respiratory Imaging) — The University of Alabama at Birmingham, BirminghamENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults — Enveda Investigative Site, BirminghamPolypill for Prevention of Cardiomyopathy — UT Southwestern Medical Center, DallasA Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2) — Research Site 13, BakersfieldSub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults — Harbor UCLA Medical Center, TorranceRandomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment — Research Site, ChandlerThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease — University of Alabama at Birmingham- Site Number : 8400003, BirminghamA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma — Velocity Clinical Research, Mobile, MobileDepemokimab Asthma Imaging and Bronchoscopy Sub-Study — GSK Investigational Site, BrooksvilleArginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease — Children's Healthcare fo Atlanta at Hughes Spalding, AtlantaMetformin IN Asthma for Overweight and Obese Individuals (MINA) — Johns Hopkins University, BaltimoreA Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma — Kymera Investigative Site, LancasterA Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma — GSK Investigational Site, Newport BeachRH Genotype Matched RBC Transfusions — Children's Hospital of Philadelphia, PhiladelphiaEASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Pinnacle Research Group, LLC, AnnistonEfficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS) — Phoenix Children's Hospital- Site Number : 8400001, PhoenixBreathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH — Rocky Mountain Regional VA Medical Center, Aurora, CO, AuroraTransplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease — University of California, Los Angeles, Los AngelesAzithromycin for Critical Asthma - Pediatrics — Johns Hopkins All Children's Hospital, St. PetersburgEscitalopram in Asthma Patients With Frequent Exacerbation — UT Southwestern, 1440 Empire Central, Ste. LD4.100, DallasCannabidiol in Sickle Cell Disease — Icahn School of Medicine at Mount Sinai, ManhattanDose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids — Research Site, BakersfieldA Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease — Sarfez Pharmaceuticals, Inc., ViennaEarly Screening and Treatment of Heart Complication in Sickle Cell Disease — Inova Schar Cancer, FairfaxStudy to Improve Deployment Related Asthma by Using L-Citrulline Supplementation — National Jewish Health, DenverZinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial — UCSF Benioff Children's Hospital Oakland, OaklandA Clinical Trial of Soluble Fiber for Asthma — Phoenix Children's, PhoenixAllo HSCT for High Risk Hemoglobinopathies — Masonic Cancer Center, MinneapolisStudy of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease — Site # 8400006, AtlantaImpact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study) — University of Texas Southwestern Medical Center, DallasA Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1) — Research Site 23, NorthridgeA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) — Memorial Sloan Kettering at Basking Ridge (Consent only), Basking RidgeFeasibility of Semaglutide in Advanced Lung Disease — University of Pennsylvania Perelman School of Medicine, PhiladelphiaA Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia — Univ of Alabama Birmingham, BirminghamA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease — University of Alabama at Birmingham, BirminghamEvaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma — Research Site, AnchoragePartial Stem Cell Transplant for Sickle Cell Disease From Matched Donors — National Institutes of Health Clinical Center, BethesdaTargeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin — University of Illinois Chicago, Sickle Cell Center, ChicagoSickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody — Children's National Hospital, Washington D.C.A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) — University Of Alabama, BirminghamEquol and Vascular Function in Women With Chronic Kidney Disease — University of Colorado Anschutz Medical Campus, AuroraA Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study — Kymera Investigative Site, TampaA Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease — University of Alabama Birmingham, BirminghamReduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders — Yale School of Medicine, New HavenAlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion — New York Medical College, Valhalla5HTP Regulation Of Asthma In Children — Indiana University, IndianapolisA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease — Uni of Alabama at Birmingham, BirminghamIntravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease — Children's National Hospital, Washington D.C.A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma — Teva Investigational Site 12087, PhoenixSafety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) — UAMS Medical Center, Little RockSafety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis — Univ. of California, San Francisco Health Care, OaklandViral Mucosal Reprogramming — University of Texas Medical Branch, GalvestonBiomarker-based Trial of NPC-1 for Alzheimer's Pathology — Massachusetts General Hospital, BostonRuxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease — Children's Hospital of Colorado, AuroraA Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure — Research Site, FairhopeA Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma — Research Site, BakersfieldAlendronate for Osteonecrosis in Adults With Sickle Cell Disease — UC Davis Comprehensive Cancer Center, SacramentoMyeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease — University of California Los Angeles, Los AngelesReslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study — National Jewish Health, DenverStudy of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease — University of Illinois at Chicago, ChicagoRelationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET — St. Jude Children's Research Hospital, MemphisMinimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease — Children's National Health System, Washington D.C.T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias — Children's Hospital of Pittsburgh of UPMC, PittsburghAnti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma — University of Colorado Anschutz Medical Campus, AuroraSupplementing L-citrulline to Overweight Late Asthma oNset Phenotypes — Duke University (Asthma, Allergy and Airway Center), DurhamTocilizumab for Acute Chest Syndrome — University of Chicago, ChicagoSympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study) — University of Kansas Medical Center, Kansas CityPulmonary Hypertension SOLAR — Duke University Medical Center, DurhamGene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesPRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis — University of Alabama at Birmingham, BirminghamSympathetic Mechanisms in Obesity-Crossover Design — Vanderbilt University Medical Center, NashvilleOmalizumab Before Onset of Exacerbations — Children's National Hospital, Washington D.C.Cognitive Remediation Intervention to Prepare for Transition of Care — University of Alabama at Birmingham, BirminghamA Phase 2/3 Study in Adult and Adolescent Participants With SCD — Smilow Cancer Hospital, New HavenEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease — New York Presbyterian Hospital - Morgan Stanley Children's Hospital, New YorkCannabinoids for the Reduction of Inflammation and Sickle Cell Related Pain — Mount Sinai Hospital, New YorkSoy Isoflavones For Inner City Infants At Risk For Asthma (SIRA) Study — Ann and Robert H Lurie Childrens Hospital of Chicago, ChicagoA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma — GSK Investigational Site, Birmingham